Status:
COMPLETED
Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
Lead Sponsor:
Washington University School of Medicine
Conditions:
Subarachnoid Hemorrhage
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in t...
Detailed Description
This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily...
Eligibility Criteria
Inclusion
- Age \>18 years of age
- Diagnosis of spontaneous SAH
Exclusion
- SAH secondary to trauma or arteriovenous malformation
- Early death (defined as death within 3 days of presentation)
- Known allergy to levetiracetam
- Know seizure history on chronic AEDs
- Pregnancy
- Current incarceration
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01137110
Start Date
May 1 2010
End Date
January 1 2017
Last Update
July 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barnes-jewish Hospital
St Louis, Missouri, United States, 63110